Post Market Surveillance of OZURDEX® for Branch Retinal Vein Occlusion (BRVO) and Central Retinal Vein Occlusion (CRVO)

Allergan

Status: Completed

Conditions: Macular Edema; Retinal Vein Occlusion

Treatments: Other: No Intervention

Study type: Observational

Funder types: Industry

Identifiers

NCT01568021

MAF/AGN/OPH/RET/007

Details and patient eligibility

About

This multicenter observational study will assess the efficacy and tolerability of OZURDEX® in clinical practice, and will assess the time at which patients are considered for retreatment.

Enrollment: 100 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Macular Edema
• Prescribed OZURDEX®

Exclusion criteria

• None

Trial design

100 participants in 1 patient group

OZURDEX®

Description:

Single dose of dexamethasone 700 ug intravitreal implant (OZURDEX®) which may be repeated over 1 year as per standard of care in clinical practice. No intervention was administered in this study.

Treatment:

Other: No Intervention